Takeda Pharmaceutical Co Ltd - Apr 28, 2022 Form 3 Insider Report for HilleVax, Inc. (HLVX)

Role
10%+ Owner
Signature
/s/ Yoshihiro Nakagawa, Global General Counsel of Takeda Pharmaceutical Company Limited
Stock symbol
HLVX
Transactions as of
Apr 28, 2022
Transactions value $
$0
Form type
3
Date filed
4/29/2022, 06:02 AM
Previous filing
Mar 16, 2022
Next filing
May 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HLVX Common Stock 500K Apr 28, 2022 See Explanation of Responses F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HLVX Warrant (Right to Buy) Apr 28, 2022 Common Stock 3.5M $0.00 See Explanation of Responses F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Takeda Pharmaceutical Company Ltd's beneficial ownership of the reported securities is comprised of 500,000 shares of Common Stock and a Warrant to purchase 3,500,000 shares of Common Stock; each held by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.